The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview

Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre

(2018) Ya-Zhen Qin et al.   BRITISH JOURNAL OF HAEMATOLOGY

No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib

(2017) Markus Pfirrmann et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Differential signaling through p190 and p210 BCR-ABL fusion proteins revealed by interactome and phosphoproteome analysis

(2017) J A Cutler et al.   LEUKEMIA

Differential signaling networks of Bcr–Abl p210 and p190 kinases in leukemia cells defined by functional proteomics

(2017) S Reckel et al.   LEUKEMIA

De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial

(2017) Richard E Clark et al.   Lancet Haematology

A population-based study of chronic myeloid leukemia patients treated with imatinib in first line

(2016) Fausto Castagnetti et al.   AMERICAN JOURNAL OF HEMATOLOGY

Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors

(2016) P. Jain et al.   BLOOD

Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients

(2016) A. K. Arun et al.   International Journal of Laboratory Hematology

Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population

(2016) Hannah Bower et al.   JOURNAL OF CLINICAL ONCOLOGY

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial

(2016) Jeffrey H Lipton et al.   LANCET ONCOLOGY

Leucemia mieloide crónica en España: sus características de presentación han cambiado. Sección española del registro poblacional EUTOS

(2016) S. Osorio et al.   REVISTA CLINICA ESPANOLA

Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study

(2015) Silvia Mori et al.   AMERICAN JOURNAL OF HEMATOLOGY

Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience

(2015) Fiorina Giona et al.   BRITISH JOURNAL OF HAEMATOLOGY

Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

(2015) Farhad Ravandi et al.   CANCER

Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib

(2015) F Castagnetti et al.   LEUKEMIA

The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries

(2015) V S Hoffmann et al.   LEUKEMIA

Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials

(2015) Koji Sasaki et al.   Lancet Haematology

Long-term outcome of chronic myeloid leukaemia patients with p210 and p190 co-expression at baseline

(2014) Matteo Molica et al.   BRITISH JOURNAL OF HAEMATOLOGY

Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib

(2014) B. Hanfstein et al.   HAEMATOLOGICA

Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML

(2013) S. Branford et al.   BLOOD

Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcripts

(2013) P. Jain et al.   HAEMATOLOGICA

Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendation

(2012) Dongho Kim et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib

(2011) D Marin et al.   LEUKEMIA

Frequencies of BCR-ABL1 fusion transcripts among Sudanese chronic myeloid leukaemia patients

(2010) Emad-Aldin I. Osman et al.   GENETICS AND MOLECULAR BIOLOGY

Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group

(2010) F. Cervantes et al.   HAEMATOLOGICA

Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts

(2009) Pratibha Sharma et al.   ANNALS OF HEMATOLOGY

Chronic myeloid leukemia with p190BCR-ABL: prevalence, morphology, tyrosine kinase inhibitor response, and kinase domain mutation analysis

(2009) A. Pardanani et al.   BLOOD

Chronic myeloid leukemia (CML) with P190BCR-ABL: analysis of characteristics, outcomes, and prognostic significance

(2009) D. Verma et al.   BLOOD

Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript

(2009) C. M. Lucas et al.   HAEMATOLOGICA

Correlation ofBCR/ABLtranscript variants with patients’ characteristics in childhood chronic myeloid leukaemia

(2008) Ronald Adler et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis

(2008) Hugues de Lavallade et al.   JOURNAL OF CLINICAL ONCOLOGY